Lipid‐lowering therapy with <scp>PCSK</scp>9‐inhibitors in the real‐world setting: Two‐year experience of a regional lipid clinic

Abstract

Patient selection by a regional lipid clinic resulted in a high real-world PCSK9i insurance approval, with efficacy and safety comparable to randomized clinical trials. Cost and medication nonadherence are potential barriers to successful implementation of therapy in routine clinical care.